Outcome of Board Meeting

25 September, 2026 National Stock Exchange of India Limited, Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Mumbai – 400051. NSE Symbol: QMSMEDI Sub.: Outcome of the Board Meeting Ref. : Intimation of Scheme of Arrangement under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (“SEBI LODR Regulations”) Dear Sir/ Ma’am, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we hereby inform that the Board of Directors of the Company at its meeting held on 25th September, 2026 and based on the recommendations of the Audit Committee and the Independent Directors Committee have inter-alia, considered and approved the following: 1. Composite Scheme of Arrangement amongst QMS Medical Allied Services Limited (“QMS” or “Demerged Company 1”) and Health Care at Home India Private Limited (“HCAH” or “Demerged Company 2”) and Saarathi Healthcare Private Limited (“Saarathi” or “Resulting Company”) and their respective shareholders under Section 230 to 232 and other applicable provisions of the Companies Act, 2013 and the rules made thereunder (“Scheme”). The Scheme shall be subject to requisite approval of shareholders and creditors of all the three companies, stock exchange i.e. National Stock Exchange of India Limited (“NSE”), the jurisdictional Hon’ble National Company Law Tribunal(s) and such other statutory approvals, permissions and sanctions of regulatory and other authorities as may be necessary. 2. Execution of a merger co-operation agreement between the Company and Conven Investment Holdings Pte. Limited, Impact Assets Pte. Ltd., Windy Investments Private Limited, Milky Investment and Trading Company, V I C Enterprises Private Limited, Mr. Mahesh Makhija, Health Care At Home Private Limited, Saarathi Healthcare Private Limited. 3. Execution of the Shareholders’ Agreement by and amongst the Conven Investment Holdings Pte. Limited, Impact Assets Pte. Ltd., Windy Investments Private Limited, Milky Investment and Trading Company, V I C Enterprises Private Limited, Mr. Mahesh Makhija and Saarathi Healthcare Private Limited. 4. To acquire 100% of the equity shares of BeamOptics Scientific Private Limited at a consideration to be determined based on the valuation report issued by an Independent Valuer. In furtherance of the above, the Company has entered into and executed a Binding Memorandum of Understanding (MOU) with the relevant parties on September 25, 2026. The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as an Annexure I, Annexure II, Annexure III and Annexure IV. CIN: L33309MH2017PLC299748; Email ID: mm@qmsmas.com The meeting of Board of Directors commenced at 3:15 P.M. (IST) and concluded at 3:50 PM (IST). Kindly take the same on records. Yours faithfully FOR QMS MEDICAL ALLIED SERVICES LIMITED TORAL BHADRA COMPANY SECRETARY AND COMPLIANCE OFFICER MEMBERSHIP NO.: A56927 DATE: SEPTEMBER 25, 2026 PLACE: MUMBAI Encl.: As above CIN: L33309MH2017PLC299748; Email ID: mm@qmsmas.com Annexure-I Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026. Particulars Details 1. Brief details of the Demerger of Healthcare Services Business (‘as defined in division(s) to be the Scheme’) of the Demerged Company 1 and Demerged demerged Company 2 (referred as Demerged Undertaking 1 and Demerged Undertaking 2 respectively in the Scheme) that is engaged in provision of services in relation to patient support programs, patient access programs, disease management programs, preventive healthcare and improved healthcare outcomes as applicable, into Resulting Company. 2. Turnover of the The turnover of demerged undertaking of QMS as on demerged division March 31, 2026 was Rs. 37.17 Crores which constitutes and as % to the total 24.41% of total turnover of QMS in the immediately turnover of the listed preceding financial year / based on financials of last entity in the financial year (year ended March 31, 2026). immediately preceding financial year / based on financials of the last financial year 3. Rationale for As the Healthcare Services Business (as defined in the Demerger Scheme) of QMS and HCAH constitutes a similar line of business with that of Saarathi, it is proposed to combine the business operations of the Healthcare Services Business of QMS and HCAH with Saarathi. The said combination shall drive focused growth, operational efficiencies and significant business synergies. The proposed demerger of the Healthcare Services Business of QMS and HCAH into Saarathi shall be in the best interests of the Demerged Company 1, Demerged Company 2 and the Resulting Company, and their respective shareholders and other stakeholders on account of the following: a) In light of the distinct profile of the Healthcare Services Business, housing the same into a separate to be listed company would enable focused management, better and efficient control and management for the CIN: L33309MH2017PLC299748; Email ID: mm@qmsmas.com Healthcare Services Business, operational rationalisation, organisation efficiency and optimum utilisation of various resources; b) Enable accelerated growth of the Healthcare Services Business to explore suitable strategies to fund its growth plan; c) Achieving synergies through consolidation, greater integration which will maximize overall shareholder value and improve the competitive position of the combined entity; d) The combined entity will benefit from increased scale, stronger market presence and improved ability to service customers. 4. Brief details of There will be no change in the shareholding pattern of the change in Demerged Company 1 and Demerged Company 2 shareholding pattern pursuant to the Scheme (if any) of all entities As regards Resulting Company, the entire existing paid- up share capital of the Resulting Company held by the Demerged Company 1 (directly and/ or through nominees) shall stand cancelled, reduced and extinguished, without any consideration and without any further act, instrument or deed, which shall be regarded as reduction of share capital of the Resulting Company, pursuant to Sections 230 to 232 of the Act as an integral part of the Scheme. Pre - Arrangement Shareholding – Resulting Company Particulars Pre Pre Arrangement Arrangement – No. of – Percentage Shares Promoters 8,25,000 100% (directly and/ or through nominees) Public - - Total 8,25,000 100% Post - Arrangement Shareholding - Resulting Company* Particulars Post Post Arrangement Arrangement – No. of - Percentage Shares* CIN: L33309MH2017PLC299748; Email ID: mm@qmsmas.com Promoters 1,31,71,586 40.5% Public 1,93,28,480 59.5% Total 3,25,00,066 100% * Note: ESOPs of HCAH are assumed to be exercised and considered on a fully diluted basis 5. In case of cash There is no cash consideration being discharged under consideration amount the Scheme or otherwise share exchange ratio Upon Part II of the Scheme becoming effective (as defined in the Scheme), and in consideration for the transfer and vesting of the Demerged Undertaking 1 from the Demerged Company 1 to the Resulting Company in terms of this Scheme, the Resulting Company shall, without any further application, act, deed, consent, instrument issue and allot on a proportionate basis its equity shares, credited as fully paid-up (the “Equity Shares of the Resulting Company”), to QMS Equity Shareholders as on the Record Date 1 in the following manner: “1 fully paid Equity Share of INR 10/- (Indian Rupees Ten) each in the Resulting Company for every 1 fully [Showing first 8,000 characters — download PDF for full document]